US0547548588 - Common Stock
AYTU BIOPHARMA INC
NASDAQ:AYTU (3/27/2024, 8:01:19 PM)
After market: 2.94 -0.14 (-4.55%)3.08
0 (0%)
Aytu Biopharma, Inc. is a specialty pharmaceutical company, which focuses on identifying, acquiring, and commercializing novel products. The company is headquartered in Denver, Colorado and currently employs 150 full-time employees. The company went IPO on 2017-10-20. The Company’s Rx segment consists of prescription pharmaceutical products and the Consumer Health segment consists of various consumer healthcare products (the Consumer Health Portfolio). The Company’s prescription products include Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets for the treatment of attention deficit hyperactivity disorder (ADHD); Karbinal ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions; and Poly-Vi-Flor and Tri-Vi-Flor, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. Its Consumer Health Segment addresses a range of common conditions.
AYTU BIOPHARMA INC
7900 E. Union Avenue, Suite 920
Denver COLORADO 80112
P: 17204376580
CEO: Joshua R. Disbrow
Employees: 150
Website: https://aytubio.com/
Dallas, Texas--(Newsfile Corp. - August 8, 2023) - Stonegate is pleased to announce the...
Aytu BioPharma (AYTU) announced on Friday the pricing of its equity offering of 1.7M shares of its common stock and accompanying Tranche A and Tranche B warrants to purchase 4.3M shares...
AYTU stock earnings show Aytu Biopharma missing earnings per share and revenue estimates for the fiscal third quarter.
Here you can normally see the latest stock twits on AYTU, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: